Alnylam Pharmaceuticals (ALNY) EV to EBITDA (2009 - 2026)

Alnylam Pharmaceuticals (ALNY) EV to EBITDA (2009 - 2026) Analysis & Trends

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	EV to EBITDA
1	Oculis Holding AG	68,785.72 Bn	68,785.72 Bn	-	-874,324.57
2	Nanobiotix	1,895.57 Bn	1,895.51 Bn	-	-155,086.11
3	BeOne Medicines	471.35 Bn	466.56 Bn	1.35 Bn	680.18
4	NuCana	279.75 Bn	279.75 Bn	-	-11,585.42
5	Vertex Pharmaceuticals	120.24 Bn	113.00 Bn	2.59 Bn	24.14
6	Regeneron Pharmaceuticals	67.80 Bn	59.04 Bn	3.31 Bn	16.27
7	Belite Bio	62.51 Bn	62.51 Bn	-	-3.55
8	Argenx Se	57.38 Bn	57.38 Bn	1.41 Bn	43.84
9	Revolution Medicines	37.78 Bn	37.78 Bn	-	-27.24
10	Alnylam Pharmaceuticals	35.71 Bn	32.70 Bn	959.66 Mn	43.48

Download Data